Generic drug: selpercatinib
Brand name: Retevmo
What is Retevmo (selpercatinib), and how does it work?
Retevmo (selpercatinib) is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in:
- adults with non-small cell lung cancer (NSCLC) that has spread.
- adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy).
- adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Retevmo is right for you. It is not known if Retevmo is safe and effective in children younger than 12 years of age.
What are the side effects of Retevmo?
- increased levels of liver enzymes
- increased blood sugar levels
- decrease in white blood cell count
- decreased protein levels (albumin) in the blood
- decreased levels of calcium in the blood
- dry mouth
- increased creatinine (kidney function test)
- high blood pressure
- swelling of your arms, legs, hands, and feet (peripheral edema)
- decrease in platelet count
- increased cholesterol levels
- decreased levels of salt (sodium) in the blood
Retevmo may affect fertility in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects with Retevmo.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Retevmo?
Select patients for treatment with Retevmo based on the presence of a RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma. An FDA-approved test for the detection of RET gene fusions and RET gene mutations is not currently available.
Important Administration Instructions
Retevmo may be taken with or without food unless coadministrated with a proton pump inhibitor (PPI).
The recommended dosage of Retevmo based on body weight is:
- Less than 50 kg: 120 mg
- 50 kg or greater: 160 mg
Take Retevmo orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.
Swallow the capsules whole. Do not crush or chew the capsules.
Do not take a missed dose unless it is more than 6 hours until next scheduled dose.
If vomiting occurs after Retevmo administration, do not take an additional dose and continue to the next scheduled time for the next dose.
Dosage Modifications For Concomitant Use Of Acid-Reducing Agents
Avoid concomitant use of a PPI, a histamine-2 (H2) receptor antagonist, or a locally-acting antacid with Retevmo. If concomitant use cannot be avoided:
- Take Retevmo with food when coadministered with a PPI.
- Take Retevmo 2 hours before or 10 hours after administration of an H2 receptor antagonist.
- Take Retevmo 2 hours before or 2 hours after administration of a locally-acting antacid.
Dosage Modifications For Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1.
Table 1: Recommended Retevmo Dose Reductions for Adverse Reactions
|Dose Reduction||Patients Weighing Less Than 50 kg||Patients Weighing 50 kg or Greater|
|First||80 mg orally twice daily||120 mg orally twice daily|
|Second||40 mg orally twice daily||80 mg orally twice daily|
|Third||40 mg orally once daily||40 mg orally twice daily|
Permanently discontinue Retevmo in patients unable to tolerate three dose reductions.
The recommended dosage modifications for adverse reactions are provided in Table 2.
Table 2: Recommended Retevmo Dosage Modifications for Adverse Reactions
|Adverse Reaction||Severity||Dosage Modification|
|Hepatotoxicity||Grade 3 or Grade 4|
|QT Interval Prolongation||Grade 3|
|Hemorrhagic Events||Grade 3 or Grade 4|
|Hypersensitivity Reactions||All Grades|
Dosage Modifications For Concomitant Use Of Strong And Moderate CYP3A Inhibitors
Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dose as recommended in Table 3. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume Retevmo at the dose taken prior to initiating the CYP3A inhibitor.
Table 2: Recommended Retevmo Dosage for Concomitant Use of Strong and Moderate CYP3A Inhibitors
|Current Retevmo Dosage||Recommended Retevmo Dosage|
|Moderate CYP3A Inhibitor||Strong CYP3A Inhibitor|
|120 mg orally twice daily||80 mg orally twice daily||40 mg orally twice daily|
|160 mg orally twice daily||120 mg orally twice daily||80 mg orally twice daily|
Dosage Modification For Severe Hepatic Impairment
Reduce the recommended dosage of Retevmo for patients with severe hepatic impairment as recommended in Table 4 [see Use In Specific Populations].
Table 3: Recommended Retevmo Dosage for Severe Hepatic Impairment
|Current Retevmo Dosage||Recommended Retevmo Dosage|
|120 mg orally twice daily||80 mg orally twice daily|
|160 mg orally twice daily||80 mg orally twice daily|
What drugs interact with Retevmo?
Effects Of Other Drugs On Retevmo
- Concomitant use of Retevmo with acid-reducing agents decreases selpercatinib plasma concentrations, which may reduce Retevmo anti-tumor activity.
- Avoid concomitant use of PPIs, H2 receptor antagonists, and locally-acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally-acting antacid).
Strong And Moderate CYP3A Inhibitors
- Concomitant use of Retevmo with a strong or moderate CYP3A inhibitor increases selpercatinib plasma concentrations, which may increase the risk of Retevmo adverse reactions, including QTc interval prolongation.
- Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of strong and moderate CYP3A inhibitors cannot be avoided, reduce the Retevmo dosage and monitor the QT interval with ECGs more frequently.
Strong And Moderate CYP3A Inducers
- Concomitant use of Retevmo with a strong or moderate CYP3A inducer decreases selpercatinib plasma concentrations, which may reduce Retevmo anti-tumor activity.
- Avoid coadministration of strong or moderate CYP3A inducers with Retevmo.
Effects Of Retevmo On Other Drugs
CYP2C8 And CYP3A Substrates
- Retevmo is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor.
- Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates.
- Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions.
- If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.
Drugs That Prolong QT Interval
- Retevmo is associated with QTc interval prolongation.
- Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.
Is Retevmo safe to use while pregnant or breastfeeding?
- Based on findings from animal studies, and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman.
- There are no available data on Retevmo use in pregnant women to inform drug-associated risk.
- There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production.
- Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the final dose.
Retevmo (selpercatinib) is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC), and adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC), advanced thyroid cancer, or thyroid cancer. The most common side effects of Retevmo include increased levels of liver enzymes, increased blood sugar levels, decrease in white blood cell count, decreased protein levels (albumin) in the blood, decreased levels of calcium in the blood, dry mouth, diarrhea, increased creatinine (kidney function test), high blood pressure, and others.
Multimedia: Slideshows, Images & Quizzes
Lung Cancer: Early Signs, Symptoms, Stages
Learn about lung cancer early warning signs, symptoms and treatments. What causes stage IV lung cancer? Get more information on...
Lung Cancer Quiz: Signs and Symptoms
Lung cancer is the number one cause of cancer deaths in both men and women in the U.S. and worldwide. Get the facts about lung...
Picture of Lung Cancer
Cancer of the lung, like all cancers, results from an abnormality in the body's basic unit of life, the cell. See a picture of...
Lung Cancer Risks: Myths and Facts
Learn about lung cancer myths and facts. Explore how cigar smoke, menthol, and pollution can increase your risk of lung cancer...
Related Disease Conditions
Lung cancer kills more men and women than any other form of cancer. Eight out of 10 lung cancers are due to tobacco smoke. Lung cancers are classified as either small-cell or non-small-cell lung cancers.
What Should I Do After an Unwanted Pregnancy?
There are a variety of options that may help you handle your situation. It might help you to visualize each option and decide how you feel about it. Consider reaching out to trained professionals or close friends if you get overwhelmed.
Small Cell Lung Cancer vs. Non-Small Cell Lung Cancer
Non-small cell lung cancers (NSCLC) consist of large cell carcinomas, adenocarcinomas, and squamous cell carcinomas. Small cell lung cancer (SCLC) usually starts in the bronchi and typically appears in those who smoke. SCLC and NSCLC are staged in different manners, and SCLC tends to metastasize more quickly than NSCLC. Signs and symptoms of NSCLC and SCLC include shortness of breath, coughing up blood, recurring lung infections, and chest pain. Treatment may involve radiation therapy, chemotherapy, and surgery.
Can Pancoast Lung Cancer Be Cured?
Pancoast tumors are a rare type of lung cancer that forms at the extreme top of either of the lungs. Due to their location at the top of the lung, there’s a high chance that cancer might attack the adjacent tissue and produce typical symptoms.
What Are the Four Types of Lung Cancer?
The four types of lung cancer are classified by what kind of cells the cancer affects and what the tumor cells look like under a microscope. Lung cancers can be small-cell or non-small cell, further classified as squamous cell carcinoma or adenocarcinoma.
Six Early Signs of Lung Cancer
Lung cancer is the third most common cancer in the United States. It may not show its signs and symptoms in its early stages. Signs and symptoms typically appear in the advanced stage of the disease.
What Is the Survival Rate of Non-Small Cell Lung Cancer?
There are two main types of lung cancers, namely, small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of all lung cancer cases in the United States. It must be noted that medical science is progressing with leaps and bounds, and treatment for lung cancer must be initiated and maintained despite the stage of diagnosis.
Treatment & Diagnosis
- Lung Cancer FAQs
- Sensitive to Smoke, Lung Cancer Gene
- Lung Cancer and Chemotherapy
- Lung Cancer Signs and Symptoms
- 5 Causes of Lung Cancer in Non-Smokers
- Dana Reeve Dies of Lung Cancer by Dr. Stoppler
- What Is the Survival Rate for Lung Cancer Nodules?
- Why Does Lung Cancer Spread So Fast?
- Can You Get Lung Cancer After Quitting Smoking?
- Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
Medications & Supplements
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.